Daily close, T-120 (10/17/24) through T+5. Run-up high $328.35 on 10/21/24, low $258.59 on 1/9/25 (T-120 to T-1). FDA decision 4/3/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 20, 2025, 14 days before the decision date, at-the-money options priced a move of ±3.5% through Apr 4, 2025 (the first listed expiry after the decision; ATM implied volatility 22%). The stock closed +1.4% at the first close across the decision and -4.8% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was UPLIZNA (INEBILIZUMAB-CDON) approved by the FDA?
Yes. The FDA approved the application for UPLIZNA (INEBILIZUMAB-CDON) on April 3, 2025. The primary source is linked on this page.
What was UPLIZNA (INEBILIZUMAB-CDON) under FDA review for?
The application covered Immunoglobulin G4-related disease (IgG4-RD). The FDA approved the application on April 3, 2025.
How did AMGN stock react to the FDA decision?
On the decision day AMGN moved +1.4%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.